Index

Note: Page numbers of article titles are in **boldface** type.

A

Adrenergic agonists

$\alpha_2$-
  - in primary glaucoma management, 1239–1240
  - in feline glaucoma management, 1326–1327
Adrenergic antagonists

$\beta$-
  - in primary glaucoma management, 1240–1243
Adrenoceptor(s)
  - drugs acting on
    - in primary glaucoma management, 1239–1243
Age
  - as factor in canine glaucoma, 1128–1130
AH. See Aqueous humor (AH)
Anterior chamber shunt procedures
  - in feline glaucoma management, 1328
Anterior segment
  - glaucoma-induced changes in, 1214–1223
  - concurrent lesions vs. insights on pathogenesis, 1219–1223
  - goniodysgenesis, 1214–1217, 1223
  - histopathologic diagnosis and challenges related to, 1217–1219
Anterior-segment optical coherence tomography (AS-OCT)
  - in ICA evaluation, 1203
Applanation tonometry
  - in IOP evaluation, 1196–1197
Apraclonidine
  - in primary glaucoma management, 1239–1240
Aqueous flare and cell
  - mild
    - as early to midstage sign of primary angle-closure glaucoma, 1193
Aqueous humor (AH)
  - in cats, 1307
  - described, 1101–1102
Aqueous outflow
  - pathways of, 1104
Aqueous production, 1102–1104
AS-OCT. See Anterior-segment optical coherence tomography (AS-OCT)
Autoimmune system
  - canine glaucoma related to, 1145–1148
B

β-Blockers
  in feline glaucoma management, 1325
Blunt trauma
  secondary glaucoma in dogs related to, 1353–1354
Breeds
  as factor in canine glaucoma, 1131
Brimonidine
  in primary glaucoma management, 1240
Buphthalmos
  as chronic clinical sign of primary angle-closure glaucoma, 1195–1196

C

Canine glaucoma. See specific types of glaucoma and Glaucoma(s), canine
Carbachol
  in primary glaucoma management, 1238
Carbonic anhydrase inhibitors
  in feline glaucoma management, 1325
  in primary glaucoma management, 1243–1245
Cats
  aqueous humor dynamics in, 1307
  glaucoma in (See Glaucoma(s), feline)
Cataract(s)
  canine, 1341–1344
    diagnostics in, 1344
    key findings in, 1341
    pathogenesis of, 1341–1344
    prognosis of, 1344
    treatment of, 1344
Cholinergic agents
  in feline glaucoma management, 1326
Cholinergic agonists
  in primary glaucoma management, 1237–1239
Choroid
  changes in
    primary glaucoma and, 1226
Choroidal thinning
  in canine eyes with primary glaucoma, 1225
Ciliary body
  chemical ablation of, 1275–1276
Ciliary body epithelium
  pharmacologic ablation of
    in feline glaucoma management, 1328
Ciliary cleft, 1107
Ciliary cleft opening
  genetics of, 1167–1168
Confocal scanning laser ophthalmoscopy
  in optic disc evaluation, 1205
  in retinal nerve fiber layer evaluation, 1209
Congenital glaucoma, 1132
   feline, 1310–1311
Corneal edema
   as early to midstage sign of primary angle-closure glaucoma, 1192–1193
Corneoscleral trabecular meshwork (CSTM), 1110–1111
Corticosteroid(s)
   topical
      in feline glaucoma management, 1327
Cribiform region or juxtacanalicular tissue and inner wall of inner collector channels, 1111–1115
CSTM. See Corneoscleral trabecular meshwork (CSTM)
Cyclodestructive techniques
   in canine glaucoma management, 1283–1305 (See also specific techniques)
      cyclophotocoagulation, 1284–1286
      diode TSCP, 1286–1290
      endoscopic cyclophotocoagulation, 1290–1301
      introduction, 1283–1284
   in feline glaucoma management, 1327–1328
Cyclophotocoagulation
   in canine glaucoma management, 1284–1286
   endoscopic
      in canine glaucoma management, 1290–1301 (See also Endoscopic cyclophotocoagulation)
   transscleral
      in canine glaucoma management, 1286–1290

D
Demecarium bromide
   in primary glaucoma management, 1238–1239
Diode transscleral cyclophotocoagulation (TSCP)
   in canine glaucoma management, 1286–1290
      complications of, 1289–1290
      postoperative management, 1288
      procedure, 1286–1288
      success rate, 1288–1289
Dipivefrin
   in primary glaucoma management, 1239
Dog(s)
   glaucoma in (See specific types of glaucoma and Glaucoma(s), canine)
   secondary glaucomas in, 1335–1364 (See also Secondary glaucomas, canine)

E
Edema
   corneal
      as early to midstage sign of primary angle-closure glaucoma, 1192–1193
Electrophysiology testing
   in visual capacity of eye evaluation, 1204–1205
Electroretinogram (ERG)
   in visual capacity of eye evaluation, 1204–1205
Endoscopic cyclophotocoagulation
  in canine glaucoma management, 1290–1301
    complications of, 1301
    postoperative management, 1299
    procedure, 1290–1292, 1294–1298
    success rate, 1299–1301
    surgical approach to ciliary processes, 1292–1294
End-stage glaucoma
  procedures for, 1274–1276
Enucleation
  in feline glaucoma management, 1328–1329
Epinephrine
  in primary glaucoma management, 1239
Episcleral injection
  as early to midstage sign of primary angle-closure glaucoma, 1192
    reduced
      as chronic clinical sign of primary angle-closure glaucoma, 1196
ERG. See Electroretinogram (ERG)
Evisceration
  in feline glaucoma management, 1328–1329
Eye(s)
  visual capabilities of
    techniques in evaluation of, 1203–1205
      electrophysiologic testing, 1204–1205
      visual field–related, 1203–1204

F
Family history
  as factor in canine glaucoma, 1130–1131
Feline aqueous humor misdirection syndrome, 1314–1316
Feline congenital glaucoma, 1310–1311
Feline glaucoma, 1307–1333. See also Glaucoma(s), feline
Feline open-angle glaucoma, 1310
Filtering procedures
  in canine glaucoma management, 1262–1263
Frontal sinus shunts
  in canine glaucoma management, 1269–1270

G
Gastrotransmitters
  in primary glaucoma management, 1249–1250
Gender
  as factor in canine glaucoma, 1130
Genetics
  of canine primary glaucoma, 1159–1182 (See also Primary glaucoma, genetics of)
Glaucoma(s)
  canine, 1127–1157 (See also specific types, e.g., Primary glaucomas)
    age as factor in, 1128–1130
    breed as factor in, 1131
classification of, 1131–1137
  congenital glaucoma, 1132
  primary glaucomas, 1133–1137
defined, 1127–1128
end-stage
  procedures for, 1274–1276
familial history of, 1130–1131
gender as factor in, 1130
goniodysgenesis as factor in, 1131
mechanisms of, 1143–1148
primary glaucomas (See Primary glaucomas)
secondary, 1335–1364 (See also Secondary glaucomas, canine)
surgical treatment of, 1261–1282
  complications of, 1271–1274
  current goniointervention in, 1263–1264
cyclodestructive techniques, 1283–1305 (See also Cyclodestructive techniques, in canine glaucoma management)
  filtering procedures in, 1262–1263
  frontal sinus shunts in, 1269–1270
  intrascleral shunts in, 1270–1271
  introduction, 1261–1262
  subconjunctival implants in, 1264–1269 (See also Subconjunctival implants, in canine glaucoma management)
  suprachoroidal shunts in, 1270
theories of, 1140–1143
end-stage
  procedures for, 1274–1276
feline, 1307–1333 (See also specific types)
  causes of, 1307–1310
  clinical management of, 1322–1323
  clinical signs of, 1316–1319
  diagnosis of, 1319–1322
  enucleation for, 1328–1329
  epidemiology of, 1307–1310
  evisceration for, 1328–1329
  medical management of, 1323–1327
    adrenergic agonists in, 1326–1327
    β-blockers in, 1325
carbonic anhydrase inhibitors in, 1325
cholinergic agents in, 1326
drugs with variable response in, 1325–1327
IOP-lowering drugs in, 1323–1325
prostaglandin analogues in, 1325–1326
topical corticosteroids in, 1327
primary glaucomas, 1310–1311
secondary glaucomas, 1312–1316
  surgical management of, 1327–1328
Glial cell activation
canine glaucoma related to, 1144–1145
Glutamate
canine glaucoma related to, 1145
Glycerin
  in primary glaucoma management, 1247–1248
Golden Retriever uveitis-related/cyst-related glaucoma, 1355–1356
Goniodysgenesis
  in anterior segment, 1214–1217, 1223
  as factor in canine glaucoma, 1131
Gonioimplant design
  current
    in canine glaucoma management, 1263–1264
Gonioscopy
  in feline glaucoma evaluation, 1321
  in ICA evaluation, 1199–1202

H
Haab striae
  as chronic clinical sign of primary angle-closure glaucoma, 1195
Heidelberg retina tomograph
  in optic disc evaluation, 1205
Hemorrhage
  intraocular
    secondary glaucomas in cats related to, 1314
Hydroxyethyl starch
  in primary glaucoma management, 1247
Hyphema
  canine, 1350–1351
Hypotensive drugs
  topical ocular
    in primary glaucoma management, 1236–1237

I
ICA. See Iridocorneal angle (ICA)
Immune-mediated diseases
  secondary glaucomas in dogs related to, 1354–1357
Immune system
  canine glaucoma related to, 1145–1148
Indentation tonometry
  in IOP evaluation, 1196
Intraocular hemorrhage
  secondary glaucomas in cats related to, 1314
Intraocular pressure (IOP)
  evaluation of
    corneal thickness effects on measurement in, 1199
    techniques in, 1196–1199
Intraocular pressure (IOP)–lowering drugs
  in feline glaucoma management, 1323–1325
Intrascleral shunts
  in canine glaucoma management, 1270–1271
IOP. See Intraocular pressure (IOP)
Iridocorneal angle (ICA), 1107
evaluation of
techniques in, 1199–1203
   AS-OCT, 1203
gonioscopy, 1199–1202
   ultrasonography, 1202–1203

L
Latanoprost
   in primary glaucoma management, 1245–1246
Lateral geniculate nucleus
   changes in
      as early to midstage sign of primary angle-closure glaucoma, 1195
Lens
   changes in
      as early to midstage sign of primary angle-closure glaucoma, 1193–1194
      primary glaucoma and, 1228
      secondary glaucomas in cats related to, 1314
Lens instability
   canine, 1344–1347
Lens luxation
   canine, 1344–1347
Lesion(s)
   microscopic
      in canine eyes with primary glaucoma, 1213–1233 (See also Microscopic lesions, in canine eyes with primary glaucoma)

M
Malaise
   systemic
      as early to midstage sign of primary angle-closure glaucoma, 1192
Mannitol
   in primary glaucoma management, 1247
Melanocytic glaucoma/pigmentary glaucoma/ocular melanosis
   canine, 1354–1355
Microscopic lesions
   in canine eyes with primary glaucoma, 1213–1233
      atrophy of inner retina, 1224–1225
      choroidal thinning, 1225
      glaucoma-induced changes in anterior segment, 1214–1223
      glaucoma-induced changes in posterior segment, 1223–1229
      introduction, 1213–1214
      optic nerve cupping, 1225
      panretinal atrophy, 1225
      scleral thinning, 1225
Miotics
   in primary glaucoma management, 1237–1239
Mitochondrial dysfunction
   canine glaucoma related to, 1143–1144
### Neoplasia
- **canine**, 1347–1349
  - diagnostics in, 1348
  - key findings in, 1348
  - pathogenesis of, 1348
  - prognosis of, 1349
  - treatment of, 1349
- **feline**
  - glaucoma secondary to, 1312

### O
- **OCT.** See Optical coherence tomography (OCT)
- **Open-angle glaucoma**
  - **feline**, 1310
- **Ophthalmoscopy**
  - in retinal nerve fiber layer evaluation, 1209
- **Optical coherence tomography (OCT)**
  - in optic disc evaluation, 1206–1207
  - in retinal nerve fiber layer evaluation, 1209
- **Optic disc**
  - changes in
    - as early to midstage sign of primary angle-closure glaucoma, 1194–1195
    - evaluation of
      - techniques in, 1205–1207
- **Optic disc imaging**
  - advanced
    - in optic disc evaluation, 1205
- **Optic disc photography**
  - in optic disc evaluation, 1205
- **Optic nerve cupping**
  - in canine eyes with primary glaucoma, 1225
- **Osmotic agents**
  - in primary glaucoma management, 1246–1248
- **Outflow facilities**
  - functional anatomy of, 1101–1126
    - angular aqueous plexus, 1115–1117
    - aqueous outflow, 1104
    - aqueous production, 1102–1104
    - posterior, uveoscleral, or unconventional outflow, 1117–1119
    - trabecular outflow, 1104–1115
- **Oxidative stress**
  - canine glaucoma related to, 1144

### P
- **Pain**
  - as early to midstage sign of primary angle-closure glaucoma, 1192
- **Panretinal atrophy**
in canine eyes with primary glaucoma, 1225
Pectinate ligament, 1107
Pectinate ligament dysplasia
genetics of, 1167–1168
Penetrating trauma
secondary glaucomas in dogs related to, 1353–1354
Photic retinopathy, 1226–1228
Phthisis bulbi
as chronic clinical sign of primary angle-closure glaucoma, 1196
Pigment-mediated diseases
secondary glaucomas in dogs related to, 1354–1357
Pilocarpine
in primary glaucoma management, 1237–1238
Posterior segment
glaucoma-induced changes in, 1223–1229
general microscopic features, 1224
Primary angle-closure glaucoma, 1134–1137
clinical forms of, 1189–1191
acute congestive, 1190–1191
chronic, 1191
intermittent, 1190
latent, 1189–1190
post congestive, 1191
clinical signs of, 1191–1196
chronic, 1195–1196
early to midstage signs, 1192–1195
corneal edema, 1192–1193
episcleral injection, 1192
lateral geniculate nucleus and visual cortex changes, 1195
lens changes, 1193–1194
mild aqueous flare and cell, 1193
optic disc changes, 1194–1195
pain, 1192
pupil alterations, 1193
retinal changes, 1194
systemic malaise, 1192
vision alterations, 1192
vitreous alterations, 1194
defined, 1185–1189
diagnosis of, 1196
genetics of, 1166–1168
pathogenesis of, 1138–1140
pathophysiology of, 1138–1140
reverse pupillary block in, 1185–1189
Primary glaucomas, 1133–1137. See also specific types
choroid changes with, 1226
clinical signs of, \textbf{1183–1212}
defined, 1183–1184
diagnosis of, \textbf{1183–1212}
emerging therapies for, 1249–1252
drug-delivery platforms for, 1251–1252
Primary (continued)
gastrotransmitters, 1249–1250
rho kinase inhibitors, 1250–1251
feline, 1310–1311
genetics of, 1159–1182
ciliary cleft opening and, 1167–1168
extracellular matrix abnormalities related to, 1165–1166
human glaucoma genetics related to, 1165
pectinate ligament dysplasia and, 1167–1168
primary lens luxation and, 1170–1171
techniques in study of, 1161–1164
introduction, 1159–1161
lens changes with, 1228
management of
strategies in, 1171
medical treatment of, 1235–1259
\( \alpha_2 \)-adrenergic agonists in, 1239–1240
\( \beta \)-adrenergic antagonists in, 1240–1243
carbachol in, 1238
carbonic anhydrase inhibitors in, 1243–1245
cholinergic agonists in, 1237–1239
mechanism of action of, 1237
demecarium bromide in, 1238–1239
dipivefrin, 1239
drugs acting on adrenoceptors in, 1239–1243
epinephrine, 1239
introduction, 1235–1236
osmotic agents in, 1246–1248
pilocarpine in, 1237–1238
prostaglandin analogues in, 1245–1246
topical ocular hypotensive drugs in, 1236–1237
microscopic lesions in canine eyes with, 1213–1233 (See also Microscopic lesions, in canine eyes with primary glaucoma)
neuroprotective therapy in, 1248–1249
pathogenesis of, 1137–1140
pathophysiology of, 1137–1140
primary angle-closure glaucoma, 1134–1137
primary open-angle glaucoma, 1137
prophylactic treatment of, 1248
scleral changes with, 1229
tapetum changes with, 1226
vitreous alterations with, 1228–1229

Primary lens luxation
genetics of, 1170–1171

Primary open-angle glaucoma, 1137
defined, 1184–1185
genetics of, 1168–1169
pathogenesis of, 1140
pathophysiology of, 1140

Prostaglandin analogues
in feline glaucoma management, 1325–1326
in primary glaucoma management, 1245–1246
Pupil alterations
as early to midstage sign of primary angle-closure glaucoma, 1193

R
Rebound tonometry
in IOP evaluation, 1197
Red-free photography
in retinal nerve fiber layer evaluation, 1209
Retina
changes in
as early to midstage sign of primary angle-closure glaucoma, 1194
inner
atrophy of, 1224–1225
Retinal detachments
canine, 1351–1353
Retinal nerve fiber layer
evaluation of
techniques in, 1207–1209
Retinal nerve fiber layer photography
in retinal nerve fiber layer evaluation, 1207–1208
Retinopathy
photic, 1226–1228
Reverse pupillary block
in primary angle-closure glaucoma, 1185–1189
Rho kinase inhibitors
in primary glaucoma management, 1250–1251

S
Scanning laser polarimetry
in retinal nerve fiber layer evaluation, 1209
Sclera
changes in
primary glaucoma and, 1229
Scleral thinning
in canine eyes with primary glaucoma, 1225
Secondary glaucomas
canine, 1335–1364
cataracts, 1341–1344
hyphema, 1350–1351
immune-mediated and/or pigment-mediated diseases, 1354–1357
introduction, 1335–1337
lens instability, 1344–1347
lens luxation, 1344–1347
neoplasia, 1347–1349
penetrating and blunt trauma, 1353–1354
retinal detachments, 1351–1353
uveitis, 1338–1341
in cats, 1312–1316
Secondary (continued)
- feline aqueous humor misdirection syndrome, 1314–1316
- intraocular hemorrhage–related, 1314
- lens-associated, 1314
- secondary to neoplasia, 1312
- secondary to uveitis, 1312–1313
- trauma-related, 1313–1314

Shunt(s)
- frontal sinus
  - in canine glaucoma management, 1269–1270
- intrascleral
  - in canine glaucoma management, 1270–1271
- suprachoroidal
  - in canine glaucoma management, 1270

Spectral-domain optical coherence tomography (OCT)
- in optic disc evaluation, 1206–1207

Subconjunctival implants
- in canine glaucoma management, 1264–1269
  - combined procedures, 1269
  - postoperative management, 1268
  - preparation for, 1264
  - success rate, 1269
  - technique, 1265–1268

T
Tapetal sparing, 1226–1228
Tapetum
- changes in
  - primary glaucoma and, 1226

Time-domain optical coherence tomography (OCT)
- in optic disc evaluation, 1206

Timolol
- in primary glaucoma management, 1240–1243

Tonometer(s)
- error sources with, 1197–1199
- in feline glaucoma evaluation, 1319–1320

Tonometry
- in IOP evaluation, 1196–1199
  - applanation tonometry, 1196–1197
  - indentation tonometry, 1196
  - rebound tonometry, 1197–1199

Topical ocular hypotensive drugs
- in primary glaucoma management, 1236–1237

Trabecular meshwork, 1107–1108
Trabecular outflow, 1104–1115
- ciliary cleft in, 1107
- cribiform region or juxtacanalicular tissue and inner wall of inner collector channels in, 1111–1115
- CSTM in, 1110–1111
- ICA in, 1107
pectinate ligament in, 1107
trabecular meshwork in, 1107–1108
USTM in, 1110–1111
UTM in, 1108–1110
Transscleral cyclophotocoagulation (TSCP) 
  diode
    in canine glaucoma management, 1286–1290
Trauma
  secondary glaucomas in cats related to, 1313–1314
  secondary glaucomas in dogs related to, 1353–1354
TSCP. See Transscleral cyclophotocoagulation (TSCP)

U
Ultrasonography
  in ICA evaluation, 1202–1203
USTM. See Uveoscleral trabecular meshwork (USTM)
UTM. See Uveal trabecular meshwork (UTM)
Uveal trabecular meshwork (UTM), 1108–1110
Uveitis
  canine, 1338–1341
    diagnostics in, 1339–1340
    key findings in, 1338
    pathogenesis of, 1338–1339
    prognosis of, 1341
    treatment of, 1340–1341
  feline
    glaucoma secondary to, 1312–1313
Uveodermatologic syndrome/Voigt-Koyanagi-Harada–like syndrome
  canine, 1356–1357
Uveoscleral trabecular meshwork (USTM), 1110–1111

V
Vision
  alterations in
    as early to midstage sign of primary angle-closure glaucoma, 1192
Visual cortex
  changes in
    as early to midstage sign of primary angle-closure glaucoma, 1195
Vitreous alterations
  as early to midstage sign of primary angle-closure glaucoma, 1194
  primary glaucoma and, 1228–1229